



AMADER GRAM BREAST CARE

A Program of
Amader Gram Cancer Care & Research Centre

CLINICAL PRACTICE GUIDELINES
Fourth version, January 2013

www.agbreastcare.org
www.ibcrf.org

CONTENTS

Items	Page
Amader Gram Breast Care Physicians and Consultants	3
Considerations in use and extent of these guidelines	4
Process metric goals for breast cancer care	5
Staging evaluation of patients with diagnosed, suspected, recurrent or metastatic invasive breast cancer	6
Laboratory staging studies in patients with clinical stage I-III invasive breast cancer	7
Evaluation of a breast mass of uncertain nature	8
Evaluation of signs and symptoms consistent with benign breast conditions, breast pain	9
Evaluation and management of nipple discharge	9
Tissue specimen collection and management for hormonal receptor and Her-2/neu testing	10
Systemic adjuvant treatments	11
Management of primary or recurrent locally advanced breast cancer	15
Adjuvant radiation therapy	15
Reports of surgical pathological examinations of breast tissues	17
Breast surgery procedures; surgical practice checklist	18
Operability	19
Management of patients with distant metastatic (stage IV) breast cancer	20
Management of complications of systemic chemotherapies	21
Assessment and management of adult cancer pain	22
American Joint Committee on Cancer (AJCC) TNM staging system for breast cancer	24
Follow up evaluation and treatment of patients without disease	25
References	27

Amader Gram Breast Care Physicians and Consultants-

Rumana Dowla M.B.B.S., M.P.H., Dip Pall Med U.K. and Asia Pacific Hospice Network
Bangladesh Palliative and Supportive Care Foundation

Syed Mozammel Hossain M.B.B.S., F.C.P.S.
(Surgery) Khulna Medical College

Richard R. Love M.D.
International Breast Cancer Research Foundation

Mohammad Golam Mostafa M.B.B.S., M.Phil.
(Pathology) National Institute of Cancer Research and Hospital

James A. Woods M.D.
International Breast Cancer Research Foundation

Ophira M. Ginsburg MSc. MD, FRCPC (Medical Oncology) Women's College Research Institute
Department of Medicine, University of Toronto

CONSIDERATIONS IN USE AND EXTENT OF THESE GUIDELINES

These guidelines are a consensus of the authors regarding currently accepted approaches to care of known or suspected breast cancer in the context of Bangladesh. Evidence from published scientific data and, in particular, uncertainty about efficacy, toxicities and cost efficacy of high-income country based guidelines for Bangladeshi women, have been important in developing these statements (Love, 2008 a). Any clinician considering these guidelines is expected to use independent medical judgment in the context of specific medical circumstances to determine any individual patient's medical treatment.

These guidelines, in the current version, cover only the commonest clinical circumstances seen with women with uncertain breast problems or diagnosed with breast cancer in Bangladesh. There are many cases in which specific information to assist in guiding best diagnostic and treatment decisions is not presented here. When this is true, the reader is urged to consult the current American NCCN guidelines (nccn.org), and carefully consider application of these to the particular patient problem.

In the face of limited data about the specific risks and benefits to Bangladeshi women from treatments for breast cancer, the authors of these guidelines have taken conservative positions, and encourage efforts to develop rigorous data to inform decisions which can benefit more women. At present, in particular evaluating the risk and benefits of systemic adjuvant therapies in any patients, involves complex estimates in individual cases. The reader is encouraged to use www.adjuvantonline.com to develop possible upper and lower estimates of benefits of these therapies. Similarly the recommendations given for drug use for management of symptoms and pain must be considered to be suggestions and careful consideration of indications and contraindications for specific drugs in individual patients must occur, and these therapies must be monitored closely by professionals.

These guidelines will be updated periodically.

PROCESS METRIC GOALS FOR BREAST CANCER CARE

DIAGNOSIS

All patients with a breast mass of undefined nature will have pathologic investigation to establish a definitive tissue diagnosis.

All patients will have all elements of the guideline-defined medical history and physical examination staging evaluations recorded in their medical record on the day of their visit.

All patients who have tissue biopsy-proven cancer will have guideline-defined laboratory staging studies completed within two weeks of the date of cancer diagnosis.

There will be a quality control program for all surgical pathology laboratory studies (including for example participation in the UK NEQAS quality control program for hormonal receptor testing).

TREATMENT

Every patient with a pathologic-established diagnosis of cancer, will have a written, medical record documented multidisciplinary group review-established plan for treatment.

Every patient with an established diagnosis of cancer will be begun on appropriate treatment of some type within three weeks of diagnosis.

There will be an annual audit by an international, external multi-disciplinary group of physicians of the records of a randomly selected sample of 15% of all patients seen during the previous year for evidence of adherence to the goals listed here, and treatment quality.

Discussion

Quality improvement should be an important routine for health care professionals. Measurement plays an important role in improvement of medical care quality.

Listed above here are specific quality indicators that are measurable, and that are suggested "starting" basic indicators for assessing quality of breast cancer care.

STAGING EVALUATION OF PATIENTS WITH DIAGNOSED, SUSPECTED, OR RECURRENT OR METASTATIC INVASIVE BREAST CANCER

*Medical history including: Characteristics of the breast problem – duration, perceived size and pain; if there is pain see “Evaluation of Signs and Symptoms consistent with benign breast conditions” specifically evaluate breast pain quantitatively; date of last menstrual period if pre- or peri menopausal; occurrence of hot flashes; signs of supraclavicular or cervical lymph node enlargement; symptoms of pulmonary or pleural metastases---cough, shortness of breath, or chest discomfort; liver area discomfort; localized long bone or spine pain; history of hepatitis.

*Physical examination including: blood pressure; height; weight; (calculated BMI); breast volume estimation+ evaluation for supra-clavicular, infra-clavicular and cervical lymph node enlargement; specific dimensions of any breast, axillary or other lymph node masses; presence/absence of extension of breast mass to the chest wall or skin, skin edema, skin ulceration, or skin nodules; if lymph node masses are found, are these fixed to one another (matted) or to other structures; cardiac and lung chest auscultation; liver palpation; gynecologic examination.

*Written documentation conveying all indicated items, for each of these evaluations in each patient’s medical record is expected to confirm that the evaluation has been carefully done.

+Breast volume/size: Estimate using standard bra sizes A,B,C, and D

LABORATORY STAGING STUDIES IN PATIENTS WITH CLINICAL STAGE I-III INVASIVE BREAST CANCER

(Anticipating that such patients will be candidates for surgical treatment)

*Chest X-ray, with specific interpretation of status of bones, pleurae, lung fields, hilar areas, and size of cardiac silhouette, with measured cardiac/thoracic ratio, provided in the interpretation report.

"While current guidelines in high income countries do not recommend a chest X ray, the high prevalence of pulmonary disease in Bangladesh, and concerns about anesthetic risk, make this test a reasonable recommendation in the Bangladeshi setting."

In usual circumstances a PA film only is indicated. If however, the presence of internal mammary lymph nodes would be of critical importance in staging, and metastatic involvement of these nodes is suspected, (as with a large or medial tumor), a lateral film should also be considered for evaluation of the anterior mediastinal space.

*Complete blood count, including a platelet count.

*Ultrasound image of the liver, with specific dimensions of any identified abnormality.

*Serum creatinine and alkaline phosphatase

*Random blood sugar

*Electrocardiogram (for patients > 30 years old)

*Urinalysis

For hyperglycemia and infection (each of which pose risks for post-operative wound infections).

NOTES:

The use of the serological markers CEA, CA15-3, and CA27.29 as markers for diagnosis, staging, or to detect recurrence after primary breast cancer therapy, is NOT recommended because "the data are insufficient" to make such recommendations (ASCO Guidelines, 2000 and 2007). (NCCN Guidelines at NCCN.org)

Creation and submission of electronic reports is recommended.

Additional radiologic imaging studies should only be considered if there are specific indications and there is a solid case that the additional testing is very likely to provide significant value to the patient and decision-making process. Radiation doses from CT scans are 100-500 times those from conventional radiography (Smith – Bindman, 2010; Puglisi, 2005; Iglehart, 2009):

*Bone scan: if the patient has localized bone symptoms and/or an elevated serum alkaline phosphatase level. (NCCN Guidelines at NCCN.org)

*Chest imaging with special chest X rays or CT scan: if the patient has pulmonary symptoms and a regular chest X ray provides inadequate information. (NCCN Guidelines at NCCN.org)

*If hepatitis history or elevation of alkaline phosphatase, serum transaminase serologies and hepatitis serologies should be considered (ASCO Guidelines, 2010).

*PET scanning is not recommended (NCCN Guidelines: www.nccn.org)

EVALUATION OF A BREAST MASS OF UNCERTAIN NATURE

EVALUATION

*Medical history: duration, size change, tenderness of any mass.

*Physical examination: specific location and dimensions; tenderness.

*Breast ultrasound examination noting: shape and size of mass; posterior acoustics; edge shadowing and vascularity.

MANAGEMENT

*If changes define a cyst, then observation.

*If changes define a very symptomatic cyst: Fine needle aspiration biopsy. Cytological examination of any fluid is NOT recommended.


*If changes define a classical fibroadenoma, then for patients under age 30, observation. For patients over age 30, management should be dictated by details of the individual case. Painful scarring after excision of fibroadenomas is common and routine excision of classical fibroadenomas is not recommended.

*If changes are consistent with an indeterminate solid lesion Core needle biopsy

EVALUATION OF SIGNS AND SYMPTOMS CONSISTENT WITH BENIGN BREAST CONDITIONS

EVALUATION for BREAST PAIN

*Medical history: Is discomfort truly mammary? Cyclical or non-cyclical; laterality; record worst and usual levels of discomfort using the following combined visual analogue scale:



*Is discomfort produced on examination? Is there definitive absence of serious abnormality and absence of breast masses?

*Breast ultrasound
Are cysts or ductal ectasia seen?

MANAGEMENT

Reassurance grounded in negative physical examination and specific ultrasound findings. Restrict caffeine intake (in medicine for example). Assure good breast support.

Consider low dose oral contraceptive.

In only extreme cases consider

Danocrine (Danazol) 100 mg daily. (A weak androgen). A trial for two months should be first considered.

Tamoxifen 10 or 20mg. (Anti-estrogen)

"A trial for 3 months can be considered. If significant relief is obtained, lowering the dose or stopping this medication should be considered."

EVALUATION AND MANAGEMENT OF NIPPLE DISCHARGE

EVALUATION

Medical history: Bloody (90% due to papilloma) versus non-bloody discharge; single duct versus multiduct discharge; spontaneous versus appearance-only-on expression pressure

MANAGEMENT

Multi-duct discharge Observation

Single duct discharge Duct excision

TISSUE SPECIMEN COLLECTION AND MANAGEMENT FOR HORMONE RECEPTOR (Estrogen and progesterone receptors) AND HER-2/NEU TESTING

Because major improvements in outcomes for patients can be made based on better choices of therapies, testing tumor tissues for hormonal receptor and HER-2/NEU is recommended for all patients with invasive breast cancers.

Complete guidelines for hormonal and HER-2/NEU testing have been published by the American Society of Clinical Oncology and the College of American Pathologists (ASCO, 2010b; Wolff, 2007). Strong consideration should be given to doing hormonal receptor testing only on core biopsy tissues because the major quality control issues--particularly pre-analytic issues---ischemic time/fixation time and sampling--- can only be well controlled in this setting (Uy, 2007; Mann, 2005).

For core biopsy specimens the following pre-analytic tissue management issues are important (Golstein, 2007; Yasiji, 2009):

*Time to fixation ("cold" ischemic time): should always be less than one hour; time should be recorded. High temperatures before fixation (for example leaving the specimen sitting in sunlight) should be avoided.

*Core biopsy or 2 mm sections/slices (including normal breast tissue) should be placed immediately into 10% neutral, buffered, room temperature, formalin for >8 at a minimum to 72 hours. (1:20 volume of tissue:volume of formalin).

Total fixation time should be recorded.

*The formalin used should be changed daily, and the pH should be maintained at >7.0.

For mastectomy specimens, the tissue should immediately be transferred to a Pathology laboratory, making sure that the pathologist is there at the time of receipt of the sample. If this is not possible, then the entire tissue specimen should be placed immediately in 10% neutral buffered formalin (1:20 volume of tissue: volume of formalin). The requisition must include information on the time the specimen was removed from the patient and also time the specimen was placed into formalin. The specimen should then be sent to the Pathology laboratory in such a way that the specimen is not exposed to direct sunlight. The specimen must be received in the Pathology laboratory within 48 hours of removal from the patient. A request to perform hormone receptor testing should accompany the specimen.

Characterization of breast cancers by genotyping and special phenotyping testing

Genotyping breast cancers has been done using different targeted gene groups, and the results have been useful in distinguishing patients with lower stage cancers that are hormone receptor positive into those who have low and higher risk for recurrence. Breast cancers are generally considered now to be of four types with the noted phenotypic or intrinsic characteristics (Goldhirsch, 2011):

LUMINAL A: Estrogen receptor positive and/or Progesterone receptor positive, Proliferation index such as Ki67 low (<14%) or grade I or II histologic grade, Her-2/neu oncogene overexpression negative.

LUMINAL B: (Her-2/neu negative) Estrogen receptor positive and/or Progesterone receptor positive, Proliferation index such as Ki67 high (>14%) or grade III histologic grade, Her-2/neu oncogene overexpression negative.

(Her-2/neu positive) Estrogen receptor positive and/or Progesterone receptor positive, Any Proliferation index level (such as Ki67) or any histologic grade, Her-2/neu oncogene overexpression positive.

HER-2/NEU: Her-2/neu oncogene overexpression positive (IHC score 3, or IHC score 2 and positive ISH test). Estrogen and progesterone receptor negative.

BASAL: —Triple negative: Estrogen receptor negative, Progesterone receptor negative, Her-2/neu oncogene overexpression negative.

Since testing for Estrogen receptor, Progesterone receptor, Her-2/neu oncogene overexpression, and histological tumor grade should be routine in practice, most tumors can be characterized as likely one of these four types, and special (very expensive) genotype testing is unlikely to be clinically useful in the overwhelming majority of cases in Bangladesh at present.

Patients with Stage I disease (T1—tumor 2 cm or less in greatest dimension; no axillary node metastases) should have individualized treatments. For these patients who have hormonal receptor positive tumors, if there are no contraindications, hormonal adjuvant therapy is a reasonable choice, with expectation that benefits will exceed risks. Tumor hormone receptor testing and Her-2/neu oncogene overexpression testing. For these patients with hormone receptor negative disease, other indicators of poorer prognosis such a tumor grade and evidence of lymph- angiticinvasion should be considered.

SYSTEMIC ADJUVANT TREATMENTS

STAGE II-III B *

The administration of these therapies and management of their toxicities are complex, and achieving best and safe outcomes for patients requires well-trained and experienced oncologic physicians, nurses and pharmacists. Tumor hormone receptor testing, accomplished following appropriate tissue management

(see above guidelines, page 10), should be strongly considered whenever possible.

Pre-menopausal women with estrogen receptor positive*** and/or progesterone receptor positive***tumors:**

Option 1: Tamoxifen 20 mg daily x 10 years (Lancet 2012). Surgical oophorectomy + tamoxifen 20 mg daily for 5 years (Love, 2008 b). It is very clear that this treatment in this subset of patients is equivalent in reducing risks for recurrence and in increasing survival in all stages of disease to standard CMF or DC chemotherapy (when those therapies are completely administered) while less costly and less toxic (Davidson, 2005)(Coates, 2012). "A large randomized trial has now clearly demonstrated that 10 years of tamoxifen therapy is better than 5 years. Toxicity and cost considerations make tamoxifen a preferable choice to aromatase inhibitor treatment in Bangladesh. One major issue is that discontinuation of treatment is common among patients in all countries"

While one study has suggested that oophorectomy in the luteal phase of the menstrual cycle may be more effective, further data are required to justify this as a guideline recommendation. This option is favored because with this surgery it is certain that the patient has received a useful treatment. Compliance with long term oral medication like tamoxifen is low in all societies.

Option 2: Tamoxifen 20 mg daily for 5 years

Pre-menopausal women with estrogen receptor negative and progesterone receptor negative tumors:**

Option 1: Chemotherapy with CMF at 21 day intervals for 6 cycles****

Option 2: Doxorubicin/cyclophosphamide at 21 day intervals for 4 cycles, particularly if tumor can be determined to be Her-2/neu over-expressing by IHC (3+IHC score)***** (EBCTCG, 2005; Pritchard, 2006; Wolf, 2007)

Option 3: Doxorubicin/cyclophosphamide at 21 day intervals for 4 cycles, followed by paclitaxel weekly for 12 weeks*****.

Postmenopausal women with estrogen receptor positive and/or progesterone receptor positive tumors:

Option 1: Tamoxifen 20 mg daily x 10 years (Lancet 2012). This option is strongly favored because letrozole and other aromatase inhibitors are more expensive and have significant adverse effects on joints (most patients developed increased arthritic symptoms; approximately 25% of patients have very severe joint symptoms), bone mineral density with increased risk for bone fractures, lipid profile and the heart, and likely on the brain. Additionally it is not at all clear that these aromatase inhibitor drugs are more effective in Bangladeshi women than tamoxifen, and if, as a general premise, they are more effective, the additional benefit must be very small. Women taking tamoxifen should be asked, whenever they are seen in follow-up visits, whether they have had any vaginal bleeding. If they have investigations for the possibility of uterine endometrial cancer must be undertaken.

Option 2: Letrozole 1 mg daily for 5 years.

Postmenopausal women with estrogen receptor negative and progesterone receptor negative tumors:

Option 1: Chemotherapy with CMF at 21 day intervals for 4 cycles**** (EBCTCG, 2005) Because of the high prevalence of sub-clinical heart disease, hypertension and diabetes among Bangladeshi women, and the marginal breast cancer benefits of an anthracycline containing chemotherapy regimens (that is doxorubicin), this option is strongly favored.

Option 2: Chemotherapy with doxorubicin/cyclophosphamide for 4 cycles***** (EBCTCG, 2005)

General guidelines for choosing among options:

Assessing level of risk

In women with operable breast cancer, risk for recurrence and risk for death increase over long time periods according to stage and details of:

- i. Presence and number of axillary nodes with metastases
- ii. Size of the primary tumor
- iii. Histologic grade of tumor or proliferation index of tumor by Ki67 assessment (low=<14%).
- iv. Other factors such as young age, lymphangitic invasion of the tumor, histo-pathologic tumor type, and evidence of extra-nodalexension of the tumor.

Increasing numbers of involved axillary lymph nodes is the most powerful adverse prognostic factor, and should usually be the most used information in assessing risks.

Risks for recurrence and death are greater for hormone receptor negative tumor bearing patients in the first 5 years after diagnosis, but fall to low levels after this, while risks for recurrence and death are lower in the first 5 years for patients with hormone receptor positive tumors but continue elevated for indefinite years afterwards, such that over long periods the absolute risks are the same regardless of hormone receptor status.

Patients with Stage II-IIIb disease

First, likelihood of completing the possible therapies needs to be considered. Patients with comorbidities—diabetes, heart disease, under-nutrition—are at much increased risks for complications and not completing chemotherapies in particular.

Second, the costs of treatment will be important to many patients. The drug costs ALONE of CMF x 4 are about Tk 5320; CMF x 6 Tk 7560; DC x 4 Tk 11,200; and DC x 4 +Paclitaxel x 12 Tk 85,960. (Other administration costs will be similar per cycle regardless of drug treatment).

Third, while relative benefits from clinical trial data in high income country populations increase from CMF x 4 to CMF x 6 to DC x 4 to DC x 4 + Paclitaxel x 12, these translate into meaningful levels (>3%) of absolute benefit only with higher risk patients. Thus a medium risk (1-3 lymph nodes positive, stage II) patient might expect a 3-5% greater survival benefit from DC treatment than CMF treatment, which if she had diabetes and heart disease might not be a big enough benefit to justify DC treatment. On the other hand if the patient had 4 or more axillary lymph nodes positive, or was stage III, the absolute survival benefit might be 6-8% or greater, and this level of benefit might justify such treatment even if the patient had heart disease.

Fourth, for high risk patients with 0-3 lymph nodes positive for whom DC chemotherapy is chosen, there is no evidence that more than 4 cycles are better (Schulman, 2012).

Fifth, DC x 4 + Paclitaxel x 12 is chosen as the most intense potentially most beneficial chemotherapy regimen. This is because of the NCCN (high income country—USA) four “preferred regimens, this is the only one that does not routinely require growth factor support which is very expensive. (NCCN Clinical Practice Guidelines in Oncology. Accessible on line at: http://nccn.org/professionals/physician_gls/PDF/breast.pdf.)

Weekly paclitaxel x 12 and three weekly docetaxel x 4 are considered equivalent therapies, but in Bangladesh, a three month course of docetaxel costs about Tk 35,000 more than three months of paclitaxel, so weekly paclitaxel is favored. The three other preferred NCCN regimens: TAC, Dose dense AC and P, and TC all require growth factor support, are very expensive and are considered risky in the Bangladeshi setting.

Finally in any case, it is a very uncertain which of the four preferred regimens is superior in any population.

As indicated above in the discussion of genotypes and phenotypes of breast tumors, tumor with positive estrogen and progesterone receptors (particularly with higher Allred scores), with I or II histologic grade, and Her-2neu negative for overexpression of oncogene, are very likely Luminal A tumors. Regardless of stage, such tumors are refractory to chemotherapy, and are best treated with hormonal treatments (Coates, 2012).

Patients with Stage IIIc disease (N3-10 axillary nodes with metastases or supraclavicular lymph node involvement) should have treatment based on the guidelines for LABC.

General considerations regarding dosing of chemotherapies

The recommended safe, conservative, and effective approach is to calculate doses based on actual body weight, administer 75% of calculated doses for the first cycle, and then, critically, to escalate doses based on individual patient's toxicity experience (Budman, 1998). This strategy accommodates uncertainty about limiting toxicity suspected to occur at higher rates in Asian populations, while attaining adequate doses which are believed to exceed critical threshold levels (Bonadonna, 1981; Budman, 1998).

The development of NCI CTC grade 3 or 4 toxicity or ANC <1500/ml³ on planned day 1 of a therapy cycle, should lead to dose reductions of 25% for all drugs in the next therapy cycle.

Explicatory footnotes

**Menopause is defined as permanent cessation of menses for 12 or more months. Thus a woman who has had a menstrual period in the preceding 12 months is considered to be pre-menopausal.

***Hormone receptor positive status is defined according to the presence of an Allred score of 3 or more (meaning that at least 1% of cells stain for receptor protein) (Harvey, 1999; Hammond, ASCO/CAP Guidelines, 2010)

****Cyclophosphamide 600 mg/m² iv day 1; methotrexate 40 mg/m² iv day 1; 5-fluorouracil 600 mg/m² iv day 1 (CMF). As noted above doses should be calculated based on actual body weight (Budman, 1998). While scientific reports of the results of CMF treatments in patients of European genetic background suggest that the "Bonadonna" 28 day regimen (with 14 days of oral cyclophosphamide) is more effective than the intravenous CMF regimen, gastrointestinal toxicity-nausea and vomiting with this regimen is frequent, and depending on availability and optimal use of anti-emetic therapies, compliance and efficacy can be low (Goldhirsch, 1998). This circumstance alters the risk-benefit ratio for Bangladeshi women. While there are not specific rigorous data on the issue of the optimal number of cycles of IV CMF, there are suggestive data that greater than four cycles are more effective. The authors have therefore chosen 6 cycles for premenopausal women. For postmenopausal women, where the absolute benefits are smaller, and the risks often greater (particularly for less-than-optimally controlled emesis and intravascular volume depletion in individuals with vascular disease), 4 cycles are recommended.

*****Doxorubicin 60 mg/M2 IV day 1 and cyclophosphamide 600mg/M2 IV day every 21 days. The same approach to optimal dose calculation, as is presented above, is advocated herefor this regimen also. Testing for Her-2/neu over-expression beyond IHC is impractical, expensive and of marginal benefit in Bangladesh. With attention to pre-analytic tissue management procedures as outlined in these guidelines, the likelihood of a 3+ IHC test being a false positive is low. With any other IHC test result, the risks and benefits suggest that NOT using this Doxorubicin regimen is the safest approach.

*****Paclitaxel 80 mg/M2 IV weekly for 12 weeks. Standard pre-medication with IV dexamethasone 20mg, IV ranitidine 50mg, IV diphenhydramine 25mg will be given prior to paclitaxel. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride to a final concentration of 0.3-1.2mg/mL. The solution is physically and chemically stable for up to 27 hours at ambient temperature (approximately 25 C) and room lighting conditions. Paclitaxel solution will be prepared and stored in glass, polypropylene, or polyolefin containers. Non-PVC containing administration sets, such as those that are polyethylene-limited, will be used. Paclitaxel will be administered through an in-line filter with a micro-porous membrane not greater than 0.22 microns.

MANAGEMENT OF PRIMARY AND RECURRENT LOCALLY ADVANCED BREAST CANCER (LABC)

In the local and systemic treatment guidelines here (Figures 1 and 2), sequential decision points for any primary or recurrent locally advanced breast tumor address:

1. Technical operability; 2. Availability of radiation therapy; and 3. Availability of tumor hormone receptor testing. Any technically operable tumor should first be treated with mastectomy and axillary node surgery. This recommendation is made because this is the one significant therapy that is always available and can be safely completed with a reasonable expectation of benefit. In patients with recurrent, essentially initially-inadequately-treated breast cancer, evolving concepts of the importance of adequate local therapy on survival, and data on revision surgery support an aggressive surgical approach, if the tumor is technically operable (Punglia, 2007; Thorat, 2008).

There are several studies suggesting that if a breast tumor is technically resectable, (i.e. safely with at least 1 cm surgical/pathological margins), there may be overall survival benefits, even if distant metastatic disease is present (Khan, 2002; Rapiti, 2006; Babiera, 2006; Blanchard, 2006; Gnerlich, 2007).

Preliminary data from an Indian randomized trial confirm that impact on survival of this approach is very unlikely to be adverse (Badwe, 2008). Thus if a patient with stage IV metastatic breast cancer has a technically operable primary breast tumor, it is recommended that mastectomy and axillary dissection should be considered. The optimal timing of this surgery is uncertain. In hormonal receptor positive disease and in lobular disease in particular, systemic hormonal therapy first to achieve optimal tumor shrinkage before surgery is advised. Similarly in hormone receptor negative disease, chemotherapy before surgery appears to be a better strategy.

Radiation therapy is a critical treatment in all cases of LABC treated with breast surgery. This need poses a major challenge in Bangladesh where at present there are approximately, 18 operating radiation therapy machines, when optimally 300 machines are needed. Absent any insurance coverage, which is the common situation of the Bangladesh, any radiation treatment costs are prohibitively high. If there is no capacity for this treatment, management of patients with LABC should be transferred to a location where such capacity IS present and can be made available to all patients needing this treatment. The role of this treatment in improving local control and thus survival has been re-emphasized recently and specific data are clear in demonstrating benefits with even "optimal" systemic approaches (Punglia, 2007; McGuire, 2007). Adjuvant radiation therapy is cost effective (Love, 2003). Thus loco-regional radiation therapy after breast surgery is recommended if at all possible.

Systemic therapies in operable LABC should be guided by results of carefully performed tumor hormonal receptor testing (Figure 2). In pre-menopausal women, adjuvant surgical oophorectomy and tamoxifen has been demonstrated to confer disease-free and overall survival benefits comparable to those achieved with anthracycline- based chemotherapy together with combined LHRH and tamoxifen therapy, and is remarkably cost-effective (Love, 2008 b; Davidson, 2005). If the patient is considered to be incurable because of systemic/distant metastatic disease, then the surgical oophorectomy/tamoxifen approach in premenopausal women with hormone receptor positive tumors, is supported by preliminary data from Torrisi, and strongly justified based on data in stage IV hormone receptor positive disease trials (Torrisi, 2004; Klijn, 2001).

In postmenopausal women tamoxifen is the treatment of choice.

In hormone receptor negative cases, the selection of optimal chemotherapies is as outlined for stage II-III B patients above. Inoperable patients, whose loco-regional disease might be anticipated to become operable with local radiation and systemic therapy, should have serious consideration given to use of radiation therapy as the primary local treatment. As the text at the far right of figure 2 notes, any patient whose local disease becomes technically operable after systemic and or radiation therapy should be considered for primary breast surgical treatment.

Adjuvant radiation therapy

There is an emerging consensus that post-mastectomy adjuvant radiation therapy is associated with both decreased risk of local-regional recurrence and increased overall survival in patients with:

* T3 (primary tumor 5 cm or greater, and/ or

* N2 (>=4-9 axillary nodes positive, or matted or fixed axillary lymph nodes),

or N3 (>=10 axillary lymph nodes positive or supraclavicular lymph node positive),

or in the presence of extra-nodal axillary cancer.


Radiation therapy in such patients should include chest wall and supraclavicular fields, and the axillary region in cases with N3 or in the presence of extra-nodal axillary cancer. Inclusion of the internal mammary nodal region is controversial.

For patients with N1 disease (1-3 axillary lymph node positive), there is not consensus about provision of adjuvant radiation therapy, but the recommendation that radiation therapy in such patients should be —strongly considered||.

A comprehensive discussion of this treatment can be found at:


<http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/Clinical+Practice+Guidelines/Postmastectomy+Radiotherapy%3A+Clinical+Practice+Guidelines+of+the+American+Society+of+Clinical+Oncology>

Figure 1
Recurrent or primary locally advanced breast cancer: local treatment.



1. If operable modified radical mastectomy with at minimum a level II axillary node dissection.
2. If radiation therapy is available, regional node/supraclavicular and internal mammary and chest wall radiation.

Figure 2
Recurrent or primary locally advanced breast cancer: systemic therapies ¹.



1. Therapies to be considered after local treatments are completed.
2. CMF (IV q21days) = Cyclophosphamide 600mg/m², mitoxantrone 40mg/m², 5-fluorouracil 600mg/m² all IV all day 1.
3. Doxorubicin/cyclophosphamide = doxorubicin 60mg/m² and cyclophosphamide 600mg/m², both IV on day 1.

REPORTS OF SURGICAL PATHOLOGICAL EXAMINATIONS OF BREAST TISSUES

CORE NEEDLE, EXCISIONAL OR INCISIONAL BIOPSIES:

Diagnosis: Invasive or In-situ If invasive, give histologic sub-type, and assessment regarding presence or absence of lympho-vascular invasion

HORMONE RECEPTOR TEST RESULTS:

Adequacy of sample: Adequate, inadequate, limited-but interpretable.

Fixation times: Not known, known –indicate duration

Assay descriptors: Methods of assay including sources and antibody clones of reagents used.

Assay interpretation: $\geq 1\%$ staining positive is the accepted cutoff. % cells staining positive, and average intensity should both be reported to give an "Allred" score.

Caveats: Fixation issues Intrinsic controls: positive or negative

MASTECTOMY SPECIMENS:

Specimen type and description (right or left)

Gross specimen findings: dimensions of apparent tumor or tumors; distances from the surgical margins; location of tumor(s) in specimen; evidence of multi-centricity; dimensions of nodal masses; See checklist at cap.org

Microscopic

- Histologic cell type (Azzopardi, WHO Classification, 1982)
- Margins for invasive and non-invasive components
- Presence of in situ component
- Histologic grade (Nottingham Index; Todd, 1987)
- Evidence of lympho-vascular invasion
- Skin or nipple involvement
- Findings in non-tumorous tissues
- Total number of lymph nodes identified (minimum should be 8)
- Number of lymph nodes with evidence of metastases
- Evidence of extra-nodal extension of metastatic disease
- Size of largest nodal metastasis

BREAST SURGERY PROCEDURES

The use of an international surgical safety checklist, as follows, is strongly recommended (Haynes, 2009).

SURGICAL SAFETY CHECKLIST ELEMENTS*

Sign in

Before induction of anesthesia, members of the team (at least the nurse and an anesthesia professional) orally confirm that:

- The patient has verified his or her identity, the surgical site and procedure, and consent
- The surgical site is marked or site marking is not applicable
- The pulse oximeter is on the patient and functioning
- All members of the team are aware of whether the patient has a known allergy
- The patient's airway and risk of aspiration have been evaluated and appropriate equipment and assistance are available.
- If there is a risk of blood loss of at least 500 ml (or 7 ml/kg of body weight, in children), appropriate access and fluids are available

Time out

Before skin incision, the entire team (nurses, surgeons, anesthesia professionals, and any others participating in the care of the patient) orally:

- Confirms that all team members have been introduced by name and role
- Confirms the patient's identity, surgical site, and procedure
- Reviews the anticipated critical events
- Surgeon reviews critical and unexpected steps, operative duration, and anticipated blood loss
- Anesthesia staff review concerns specific to the patient\
- Nursing staff review confirmation of sterility, equipment availability, and other concerns
- Confirms that prophylactic antibiotics have been administered ≤60 min before incision is made or that antibiotics are not indicated
- Confirms that all essential imaging results for the correct patient are displayed in the operating room

Sign out

- Before the patient leaves the operating room:
- Nurse reviews items aloud with the team
- Name of the procedure as recorded
- That the needle, sponge, and instrument counts are complete (or not applicable)
- That the specimen (if any) is correctly labeled, including with the patient's name
- Whether there are any issues with equipment to be addressed
- The surgeon, nurse, and anesthesia professional review aloud the key concerns for the recovery and care of the patient

*This checklist is based on the first edition of the WHO Guidelines for Safe Surgery.

Operability (Greene, 2002; Haagenson, 1943; Singletary, 2002);

Strong contraindications

- Extensive (1/3rd of breast) edema of the breast skin
- Inflammatory signs-erythema and skin edema (T4d)
- Satellite tumor nodules in the skin (T4b)
- Arm edema because of extensive axillary node disease
- Fixation of tumor to chest wall (T4a)
- Axillary lymph nodes fixed to skin or axillary tissues
- Intercostal or parasternal nodules
- High tumor-to-size-of-breast ratio.
- Unachievable tumor free margins of at least 1 cm.

Relative contraindications

- Skin ulceration (T4b)
- Axillary lymph nodes ≥ 2.5 cm
- Supraclavicular lymphadenopathy (N3c)

PRIMARY BREAST SURGERY PROCEDURES and operative report

Clinical trial data are clear in indicating that there is no survival or local recurrence advantage with muscle removal (radical mastectomy) unless there is actual invasion of the tumor thru the fascia into the muscle- and even then , only appropriate 1-2 cm margins are required- not total pectoral muscle removal.

A clear description of:

- Left or right breast procedure
- Pre and post operative diagnoses
- ALL tumor parameters- exact sizes and locations (including the o'clock position and the anterior/posterior position in the breast)
- Clinical evidence of skin and/or nipple involvement Clinical examination of axilla with axilla "open"
- Description of any muscle and/or chest wall involvement with
- precise locations Exact anatomic description of extent of nodal involvement and
- resection Any complication such as intercostal brachial nerve preservation or removal; any injury to long thoracic or
- thoracodorsal nerves; injury to axillary vein /artery.
- Blood loss.

AXILLARY NODAL SURGERY PROCEDURES for

Anatomically defined level I and II apparent disease

With 8-10 nodes at minimum evaluated.

INDICATIONS FOR COMPLETE (TO LEVEL III) AXILLARY DISSECTION:

Level III is defined as medial to the superior border of the pectoralis—the terms subclavicular or apical are also used to describe lymph nodes in this area. Any evidence of metastatic involvement in interpectoral (Rotter's) or level I or II axillary lymph nodes is indication for a level III axillary dissection. (Thorat, 2008)

Sentinel Node biopsy

Presumably for clinically axillary node negative patients only.

MANAGEMENT OF PATIENTS WITH DISTANT METASTATIC (STAGE IV) BREAST CANCER

HISTORY AND PHYSICAL EXAMINATION □ SEE STAGING EVALUATION GUIDELINE, PAGE 6
LABORATORY EVALUATION STUDIES-

- Chest X-ray
- Complete blood count
- Ultrasound image of the liver
- Serum creatinine and alkaline phosphatase

If specifically indicated by localized bone symptoms, plain radiographs of specific symptomatic bones should be performed.

When the tissue – obtaining procedure can be safely accomplished, and when patient financial resources will allow it, strongly consider biopsy of likely metastatic tissue for determination of this parameter. With liver metastases discordance of 20% between primary and liver metastatic lesions has been reported (Locatelli, 2010).

When lytic bone metastases are present and expected survival >3 months, creatinine < 2.0 mg/dl, and serious dental disease is absent (a risk factor for jaw osteonecrosis) □ Consider oral bisphosphonate therapy with clodronate 1600 mg by mouth daily (Hillner, 2003) or Pamidronate or Zoledronate intravenously every 4 weeks. □

HORMONE RECEPTOR POSITIVE (ER AND/OR PR POSITIVE) (see footnote page 11)

Premenopausal* □ Surgical oophorectomy + tamoxifen 20 mg daily

Postmenopausal* □ Tamoxifen 20 mg. daily

Second line hormonal therapies should be strongly considered in patients who have had useful responses to one hormonal treatment. After tamoxifen, megestrol, aromatase inhibitors (anastrozole, letrozole, exemestane), or ethinyl estradiol are equivalent therapies.

HORMONE RECEPTOR NEGATIVE OR NO RESPONSE TO HORMONAL THERAPY (IES):

Option 1: Oral methotexate (2.5 mg twice daily two days per week) and oral cyclophosphamide (50 mg daily). This metronomic oral methotrexate/cyclophosphamide regimen is selected as the therapy of choice because of significant levels of efficacy demonstrated in patients with metastatic cancer treated with this regimen, with low toxicity and low financial cost (Bottini, 2006; Colleoni, 2002). Given that the major goal of treatment for metastatic disease is palliation, these features of treatment are very important.

Other options:

2. CMF, DC, paclitaxel, as used for adjuvant treatments selected according to individual patient circumstances (life threatening illness e.g.) and previous therapies. It should be noted that there are some data indicating that in situations where CMF has been given as adjuvant treatment, and then at least two years or more later, metastatic disease appears, CMF has been a useful metastatic treatment.
3. Single agent doxorubicin 20 mg/M² weekly. Doxorubicin is an extraordinarily effective drug in some patients with metastatic disease, perhaps most often in those patients with extensive soft tissue disease, sometimes resulting in very long term complete remissions. Weekly treatments with good antiemetic coverage can be very well tolerated.
4. Capecitabine, an oral form of 5 fluorouracil, given 1000 mg/m² bid x 14 days every 21 days can be useful particularly with widespread bone disease. Daily antiemetic therapy makes this a more tolerable regimen. The drug is expensive: a course of 3 cycles costs Tk 41,160.
5. Gemcitabine course of 3 cycles 800 mg/m² IV days 1,8,15 every 28 days. Again this is expensive—the drug alone costs Tk 57,330 for three cycles.

*Menopause is defined as permanent cessation of menses for 12 or more months. Thus a woman who has had a menstrual period in the preceding 12 months is considered to be pre-menopausal.

MANAGEMENT OF COMPLICATIONS OF SYSTEMIC CHEMOTHERAPIES

NAUSEA, VOMITING

If related to disease in which the mechanism is prokinetic:

- Metoclopramide (Metocol, Motilon 10mg tablets; suspension 5mg/5ml; Injectable 10mg/2ml)
Starting dose: 10mg every 8 hours or as needed for nausea not requiring continual therapy.
This is the maximal dose and frequency.
 - Domperidon (Omidon 10 mg tablets) Starting Dose: 10mg -20mg every 8 hours or as required for a maximum of 3 to 5 days. This is the maximal dose and frequency.

If **Chemotherapy** related:

5HT3 blocker.

- Ondansatron 8mg (Onaseron 8mg tablets; Injectable 4mg or 8mg/5ml)(Onsat, Osetron, Emisat 8mg tablets; 8mg/4ml injectable) Starting dose: 8 mg every 8 hours. Usually this medicine is continued for 3 days. In the setting of chemotherapy administration, standard practice is to give 8mg intravenously at initiation of chemotherapy with CMF and DC, followed by 8 mg orally every 8 hours for three days. If patients have any vomiting on the day after receiving chemotherapy, IV fluid infusion and IV ondansetron should be given (again).

If **Morphine** related

Dopamine receptor blocker.

- Haloperidol (Halop 5mg tablets)
Starting dose: 2.5 mg (one half tablet) at night or 1.5 mg every 12 hours.

NEUTROPENIA:

Neutropenia is defined as an absolute neutrophil count <1500/ml.

If there is fever with neutropenia, look for a specific cause, and treat that cause with an appropriate antibiotic. If no specific infectious site or cause is identified, begin a broad spectrum antibiotic such as Ceftriaxone.

36

Neutropenia on day 1 of chemotherapy

- Delay of chemotherapy until neutropenia is resolved AND make a 25% dose reduction in each of the chemotherapy drugs for **ALL** future treatments.

DIARRHEA


If the principle cause appears to be previously administered chemotherapy:

- Loperamide (Imotil, Lomosec 2mg)
Starting dose: Two tablets immediately and then every 2-4 hours to a maximum of 6 tablets per 24 hours.
Combined with oral hydration.


ASSESSMENT AND MANAGEMENT OF ADULT CANCER PAIN

Ask: Does the patient report having any pain?

- If yes: Score pain using the following combined visual analogue scale:



1. Wong B, Hackettberry L, Wain D, Macdonald SB, Schwartz P. *Essentials of Pediatric Nursing*, 6th Edition, St. Louis, 2011, page 301. Copyright by Mosby Inc.
2. *Nurse Pain Management, Operative or Medical Procedures and Trauma, Clinical Practice Guidelines No. 1*, ACPDR Publication No. 12/0002, February 1992. Agency for Healthcare Research & Quality, Rockville, MD, pages 116-117.



VISUAL ANALOGUE SCALE

Definitions-


Mild pain : Score 1-3

Moderate pain : Score 4-6

Severe pain : Score 7-10

MANAGEMENT

The World Health Organization guideline step-ladder approach is recommended as follows (WHO, 2009):



NSAIDs: Non steroidal anti-inflammatory drugs

- Diclofenac (Mobifen, Voltaren) 50 mg
Starting dose: 50 mg every 8 hours with food.
- Ketorolac Trimethamine (Minolac, Rolac 10mg) 10 mg every 8 hours
If taken for more than several days round the clock, these drugs can cause stomach ulceration. If such treatment is used, then consideration should be given to adding anti-ulcerant drugs also.

Nonopioid analgesic

- Paracetamol (Napa, Xcel) 500mg tablet; Suspension 125mg in 5 ml)
Starting doses are 1 gm every 6 hours

Weak opioid

- Tramadol 50mg, 100mg tablets; 100mg/1ml/injectable. (Anadol, Lucidol, Tendia, Winpain)
Starting dose is 50 mg every 8 hours.

Strong Opioid

- Morphine is available in oral doses as sustained release tablets of 15mg and 30 mg and in injectable form with 15mg in a 1 ml vial.
Starting dose: 15 mg every 12 hours (because immediate release morphine is not available).

>Breakthrough pain (sudden increased pain): Three options:

1. One capsule Tramadol 50mg (because immediate release morphine is not available).
2. Buccal Fentanyl tablet (Opi-Fen) 100 mg. tablet.
3. Injection morphine via insulin syringe subcutaneously at one sixth of daily total dose.

Whenever regular morphine administration is anticipated, it should be given together with a laxative drug such as Laxena, two tablets at bedtime, to prevent constipation.

Adjuvants commonly used along with opioids are:

Anxiolytic drugs such as-

- Lorazepam (a short acting benzodiazepine) 1mg tablets. (Lozicum)
Starting dose: 1 mg once a day.
- Bromazepam 3mg tablets. (Lexotenil, Laxyl) may be preferred in patients with insomnia.
Starting dose: 1.5 mg (Half a tablet) at bedtime.

The goal should be to achieve and maintain freedom from pain. To reach this goal drugs should be given "by the clock", that is every 3-6 hours, rather than "on demand"
This WHO three-step approach emphasizes administering the right drug in the right dose at the right intervals.

Watson, 2004; Watson 2006.

American Joint Committee on Cancer (AJCC) TNM staging system for breast cancer

A revised version of this system will be available in the summer of 2009 and will be posted here at that time. . Until this time the reader is encouraged to access the current staging system at-

NCCN Clinical Practice Guidelines in Oncology. Accessible on line at:
http://nccn.org/professionals/physician_gls/PDF/breast.pdf

Note that in the revised system patients with 4-9 axillary lymph nodes positive are N2 (and therefore always at least stage IIIA), and patients with 10 or more axillary lymph nodes positive are N3 (and therefore always at least stage IIIC).

Follow up evaluation and treatment of patients without disease

The goals of follow-up evaluations are to-

1. Detect recurrent disease in potentially more manageable stages and lesser extents.
2. Identify complications of treatments.
3. Detect second primary malignancies in potentially curable stages. The commonest of these are second breast cancers, uterine and colon malignancies.

*Medical history including: date of last menstrual period if pre- or peri-menopausal, occurrence of hot flashes, signs of supraclavicular or cervical lymph node enlargement; symptoms of pulmonary or pleural metastases---cough, shortness of breath, or chest discomfort; liver area discomfort; localized long bone or spine pain.

*Physical examination including: blood pressure; height; weight; (calculated BMI); breast volume estimation; evaluation for supra-clavicular, infra-clavicular and cervical lymph node ; specific dimensions of any breast, axillary or other lymph node masses; cardiac and lung chest auscultation; liver palpation; gynecologic examination.

No "routine" laboratory or radiologic studies are recommended based on data from two randomized studies and one set of American recommendations (Roselli, 1994; GIVO investigators, 1994; Smith, 1998).

Similarly, the use of the serological markers CEA, CA15-3, and CA27.29 as markers for diagnosis, staging, or to detect recurrence after primary breast cancer therapy, is NOT recommended because "the data are insufficient" to make such recommendations (ASCO Guidelines, 2000 and 2007).

With data now available showing longer term treatment (10 years) with tamoxifen is superior to shorter term treatment (5 years), and data showing that beginning tamoxifen after intervals with no therapy is useful in reducing g risk of recurrence, serious consideration should be given to restarting tamoxifen in patients who have had less than 10 years of treatment, if they have had strong indications for hormonal therapy (Estrogen and Progesterone receptor positive tumors—Luminal A phenotype) higher stage disease (IIA or greater), and have had no complications from treatment— such as deep venous thrombosis, or vaginal bleeding (Davies, 2012; Delozier, 1997; Love, 1999). With axillary node positive disease, recurrence rates between years 5 and 10 after diagnosis, after 5 years only of tamoxifen treatment average about 3%/year.

REFERENCES

- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer *J ClinOncol* 2007; 25: 5287-5312.
- ASCO 2010: American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. *J ClinOncol* 2010; 28:3199-3202.
- ASCO 2010b: American Society of Clinical Oncology College of American Pathologists' Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J ClinOncol* 2010; 28:2784-2795.
- Azzopardi, JG, Chepik, OF, Hartman, WH, et al. The World Health Organization histological typing of breast tumors, 2nd ed. *Am J ClinPathol* 1982; 78: 806.
- Babiera, G.V., Rao, R., Feng, L. , et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. *Ann SurgOncol* 2006; 13:776-782.
- Badwe, R. Hawaldar, R.W. Khare, A. et al. Role of local-regional treatment in metastatic breast cancer at presentation: A randomized trial. *Proc ASCO 2008 Breast Cancer Symposium*.P.210. Abst. 250.
- Beith, JM, Goh, BC, Yeo, W, et al. Inter-ethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. *Proc Am SocClinOncol* 21:2002 (abstract 252)
- Blanchard, D.K., Bhatia, P., Hilsenbeck, S.G. et al. Does surgical management of stage IV breast cancer affect outcome? (abstract 2110). *Breast Cancer Res Treat* 100 (suppl 1):S118, 2006.
- Bonadonna, G Zambetti, M Valagussa, P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten year results.*JAMA* 1995; 273:542-7.
- Bonadonna, G Valagussa, P. Dose-response effect of adjuvant chemotherapy in breast cancer. *New Engl J Med* 1981; 304:10-15.
- Bottini, A. Generali, D. Brizzi, M.P. et al Randomized phase II trial of letrozole and letrozole plus low dose metronomic oral cyclophosphamide as primary systemic therapy in elderly breast cancer patients. *J Clin Oncol* 2006; 22:3623-28.
- Budman, D.R. Berry, D.A. Cirincione, C.T. et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. *J Natl Cancer Inst* 1998; 90:1205-11.
- Colleoni, M. Rocca A, Sandri, M.T. et al Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer. *Ann Oncol* 2002; 13:73-80.
- Davidson, N.E., O'Neill, A.M., Vukov, A.M. et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer. Results from INT 0101 (E5188). *J ClinOncol* 2005; 23:5973-5982.
- Dunnwald, L.K. et al Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. *J ClinOncol* 2008; 26:4449-4456.
- Early breast cancer trialists' collaborative group (EBCTCG). Effects of chemotherapy and hormonal therapy on recurrence and 15 year survival: an overview of the randomized trials. *Lancet* 2005; 365:1687-1717.

GIVO investigators. Impact of follow-up testing on survival and health related quality of life in breast cancer patients. A multicenter randomized controlled trial. *JAMA* 1994 ; 271 : 1587-92.

Gnerlich, J. Jeffe, D.B., Deshpande, A.D., et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. *Ann SurgOncol* 2007; 14:2187-2194.

Goldhirsch, A. Coates, A.S. Colleoni, M. et al. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. *J ClinOncol* 1998; 16:1358-1362.

Goldstein, Hewitt, Taylor, et al. Recommendations for improved standardization of immunohistochemistry. *ApplImmunohistochemMolMorphol* 2007; 15:124-133

Greene, F.L., Page, D.L., Fleming, I.D. et al. eds. *AJCC Cancer Staging Manual*, 6th ed. New York, NY. Springer-Verlag, 2002.

Haagensen, CD, Stout, AP, Carcinoma of the breast: II. Criteria of operability. *Ann Surg* 1943; 118:859-870; 1032-1051.

Harvey, J.M. Clark, J.M. Osborne, C.K. Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to endocrine therapy in breast cancer. *J Clin Oncol* 1999; 17:1474-1481.

Haynes, A.B., Weiser, T.G., Berry, W.R. et al. A surgical safety checklist to reduce morbidity and mortality in a global population. *New Engl J Med* 2009; 360:491-99.

Hammond, M.E.H., Hayes, D.F. Dowsett, M., et al: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. *J ClinOncol* 2010; 28:2784-2795.

Hillner, B.E. Ingle, J.N., Chlebowski, R.T. et al. American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. *J ClinOncol* 2003; 21:4042-4057.

Iglehart, J.K. Health insurers and medical imaging policy-a work in progress. *New Engl J Med* 2009; 360:1030-1037.

Khan, S.A. Stewart, A.K. Morrow, M. Does aggressive local therapy improve survival in metastatic breast cancer? *Surgery* 2002; 132:620-7.

Klijn, J.G.M., Blamey, R.W., Boccardo, F. et al. Combined tamoxifen and luteinizing hormone (LHRH) agonist alone in premenopausal advanced breast cancer: A metanalysis of four randomized trials *J Clin Oncol* 2001; 19:343-353.

Locatelli, M.A. et al: Should liver metastases be biopsied to improve treatment choice? *J ClinOncol Supplement* 2010; 28 18s, 958s. Abst CRA 1008.

Love, R.R. Defining a global research agenda for breast cancer. *Cancer* 2008; 13: 2366-71 (suppl) (a)

Love R.R., Duc NB, Binh NC, Mahler PA, Thomadsen BR, Long NH, Shen T-Z, Havighurst TC. Postmastectomy radiotherapy in premenopausal Vietnamese and Chinese women with breast cancer treated in an adjuvant hormonal therapy study. *Int J RadiatOncolBiol Phys.*, 2003; 56:697-703.

Love, R.R., Van Dinh, N., Quy, T.T., et al. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. *J ClinOncol* 2008; 26:253-257. (b)

Mann, GB, Fahey, VD, Feleppa, F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. *J ClinOncol* 2005; 23:5148-5154.

McGuire, S.E., Gonzalez-Angulo, A.M., Huang, E.H. et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathological complete response to adjuvant chemotherapy. *J Radiat Oncol Biol Phys* 2007; 68:1004-1009.

Paik, S., Bryant, J. Park, C. et al. erb-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor-negative breast cancer. *J Natl Cancer Inst.* 1998; 90:1361-1370.

Paik, S. Bryant, J. Tan-Chiu, E., et al. Her2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. *J Natl Cancer Inst* 2000; 92:1991-1998.

Pritchard, K.I. Shepherd, L.E. O'Malley, F.P. et al. Her-2 and responsiveness of breast cancer to adjuvant chemotherapy. *New Engl J Med* 2006; 354:2103-211.

Puglisi, F. Baseline staging tests after a new diagnosis of breast cancer. *Ann Oncol* 2005; 16:263-266. Punglia, R.S., Morrow, M., Winer, E.P., and Harris, J.R. Local therapy and survival in breast cancer. *New Engl J Med* 2007; 356:2399-405.

Rapiti, E. Verkooijen, H.M., Vlastoc, G. et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. *J ClinOncol* 2006; 24:2743-2749.

Rosselli Del Truco, M., Palli, D., Cariddi, A., et al. Intensive diagnostic follow up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer Follow up. *JAMA* 1994; 271:1593-1597.

Singletary, S.E., Allred, C. Ashley, P. et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. *J ClinOncol* 2002;20:3629-3636.

Smith, T.J., Davidson, N.E., Shapira, D.V. et al.: American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. *J ClinOncol* 1999; 17:1080-82.

Smith-Bindman, R. Is computed tomography safe? *N Engl J Med* 2010; 363:1-4.

Thor, A.D., Berry, D.A. Budman, D.R. et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node positive breast cancer. *J Natl Cancer Inst* 1998; 90: 1346-1360.

Thorat, MA, Rangole, A, Nadkarni, MS. Et al. Revision surgery for breast cancer. *Cancer* 2008; 113:2347- 52 (suppl).

Todd, JH, Williams, MR, Confirmation of prognostic index in primary breast cancer. *Br J Cancer* 1987; 56:489.

Torrisi R, Colleoni M, Magni E, et al. Endocrine and chemoendocrine primary therapy in premenopausal women with endocrine responsive breast cancer: a feasibility study. *Breast Cancer Res Treat* (2004) 88. (Abstr 2101).

Uy GB, Laudico AV, Fernandez AM, Lim FG, Carnate JM, Rivera RR, Meis PM, Love RR. Immunohistochemical assay of hormone receptors in breast cancer at the Philippine General Hospital: Importance of early fixation of specimens. *Philipp J Surg Spec* 2007; 62: 123-127.

Wolff, A.C., Hammond, M.E., Schwartz, J.N., et al. ASCO/CAP Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J ClinOncol* 2007; 25:118-147.

Watson, M., Lucas, C.: *Oxford Handbook of Palliative Care*. 2004. Oxford University Press.

Watson, M., Lucas, C.: Adult Palliative Care Guideline 2006 South West London Cancer Network.

World Health Organization, 2009 <http://www.who.int/cancer/palliative/painladder/en/>

Yaziji, Taylor Goldstein et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. *Applied Immunohistochemistry Mol Morphology*.

Davies, C., Pan, H-C., Godwin, J. et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet: Early Online Publication*, 5 December 2012 doi:10.1016/S0140-6736(12)61963-1

Coates, A.S. Colleoni, M., Goldhirsch, A.: Is adjuvant chemotherapy useful for women with Luminal A breast cancer? *J Clin Oncol* 2012; 30 1260-1263. 2012

Delozier T, Switsers O, Genot JY, Ollivier JM, Hery M, Namer M, et al. Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial. *Bull Cancer* 1997;84:25-30.

Goldhirsch, A. Wood, W.C., Coates, A.S., et al.: Strategies for subtypes: dealing with the diversity of breast cancer—Highlights of the St. Gallen International Expert Consensus on the Primary therapy of Early Breast Cancer 2011. *Ann Oncol* 2011; 22:1736-1747.

Love RR, Olsen MR, Havighurst TC. Delayed adjuvant tamoxifen in postmenopausal women with axillary node-negative breast cancer: mortality over 10 years. *J Natl Cancer Inst* 1999; 91(13):1167-1168.

Schulman, L.S., Cirincione, C.T., Berry, D.A., et al.: Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. *J Clin Oncol* 2012; 30:4071-4076.